Advances and unmet needs in the management of proliferative lupus nephritis: evidence, guidelines, and emerging therapies. (PubMed, Kidney Res Clin Pract) - Jun 3, 2026 - "Although mycophenolate-based regimens and cyclophosphamide remain standard induction therapies, up to one-third of patients have refractory disease, and many fail to achieve a complete renal response, as demonstrated in the ASPREVA, AURORA, and BLISSLN trials...Belimumab improves composite and complete renal response rates when added to standard therapy and reduces renal events, particularly in patients with proliferative histology. Voclosporin, a novel calcineurin inhibitor with predictable pharmacokinetics, increases complete renal response rates and rapidly reduces proteinuria in patients with preserved kidney function...Obinutuzumab, a type II anti-CD20 monoclonal antibody, demonstrated higher complete renal response rates than placebo in a phase 3 trial, albeit with increased serious infections. Anifrolumab, which targets type I interferon signaling, has shown favorable trends in reducing proteinuria and systemic disease activity in early lupus nephritis studies..."
IO biomarker • Journal • Glomerulonephritis • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Renal Disease • Systemic Lupus Erythematosus • CD40
|